SparingVision named a ‘Fierce 15’ Company by Fierce Biotech

SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, announces that it has been named by Fierce Biotech as one of 2023’s ‘Fierce 15’ biotechnology companies, designating it as one of the most innovative and promising biotechnology companies in the industry.

Stéphane Boissel, President and Chief Executive Officer of SparingVision, said: “We are honored to be recognized among the prestigious Fierce 15 as a leading innovator in the biotech sector. This achievement underscores our commitment to tackling the urgent medical need of patients affected by blinding retinal diseases, and the strides we have made in developing a diverse portfolio of cutting-edge, genomic medicine products for ocular diseases. We eagerly anticipate the milestones ahead, particularly the progression of our ongoing first-in-human Phase I/II trial for SPVN06, PRODYGY in retinitis pigmentosa.”

Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare said: “For the past 21 years, we have assessed hundreds of early-stage companies for inclusion in the ‘Fierce 15’ special report. To curate this list, we consider a diverse range of factors, including the robustness of their technology, partnerships, venture support and their competitive positioning within the market. Our special report celebrates innovation and creativity in the face of intense competition.”

This year’s full list of winners can be viewed here.